Ocera Therapeutics Inc. (NASDAQ:OCRX) shares dropped 2.4% on Monday . The stock traded as low as $2.35 and last traded at $2.39, with a volume of 1,060,597 shares changing hands. The stock had previously closed at $2.45.

Separately, Zacks Investment Research upgraded Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research report on Tuesday, April 26th.

The firm’s market capitalization is $52.44 million. The company’s 50 day moving average price is $2.57 and its 200-day moving average price is $2.72.

Ocera Therapeutics (NASDAQ:OCRX) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.02. On average, equities analysts anticipate that Ocera Therapeutics Inc. will post ($1.34) EPS for the current fiscal year.

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.